SABS
SABS
NASDAQ · Biotechnology

Sab Biotherapeutics Inc

$4.17
+0.19 (+4.77%)
As of Feb 8, 2:05 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 92.27M 83.15M 89.97M
Net Income 5.58M 4.38M 5.69M
EPS
Profit Margin 6.1% 5.3% 6.3%
Rev Growth -8.1% +18.1% +3.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 83.44M 77.12M 70.96M
Total Equity 98.15M 101.26M 94.04M
D/E Ratio 0.85 0.76 0.75
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 11.07M 10.58M 10.22M
Free Cash Flow 5.66M 4.59M 4.29M